Abstract: A method or system can be configured to receive content associated with a scene; optionally, format the content as a three-dimensional image; render the content or three-dimensional image in a display-readable format; optionally, authenticate the display; and display the formatted content such that the formatted content is perceivable as three-dimensional for one or more viewers.

Abstract: A system and/or method can be operable to receive a plurality of views of one or more scenes (e.g., from different perspectives) and generate a lightfield image and/or lightfield video from the plurality of views. The generated lightfield image and/or lightfield video can be encoded, transmitted, and/or decoded, for instance to facilitate sharing of the lightfield image and/or light field video.

Abstract: A system and method can include receiving a set of views, encoding the set of views, and displaying the set of views such that they are perceived as a holographic image.

Abstract: A method or system can be configured to receive content associated with a scene; optionally, format the content as a three-dimensional image; render the content or three-dimensional image in a display-readable format; optionally, authenticate the display; and display the formatted content such that the formatted content is perceivable as three-dimensional for one or more viewers.

Abstract: A system and method can include receiving a set of views, encoding the set of views, and displaying the set of views such that they are perceived as a holographic image.

Abstract: A system and method can include receiving a set of views, encoding the set of views, and displaying the set of views such that they are perceived as a holographic image.

Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

Abstract: Described herein are compounds of Formula (I?), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.

Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R 6, R7, R12, RXX, Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): wherein X1, X2, X3, X4, X5, X6, X7, Y, Rc, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: Certain examples provide systems and methods for improved perinatal workflow. An example system includes a user interface to display a time continuum of live data for a selected patient. The user interface includes a compressed view of the time continuum of live data over a first time period; an expanded view of the time continuum of live data over a second time period, the second time period to be shorter than the first time period; one or more indicators to be associated with data shown in the expanded view, each indicator to indicate a point of interest in the data; a first control to change the second time period for the expanded view display; and a second control to mark an indicator with respect to the data shown in the expanded view of the time continuum of live data.

Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.

Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

Abstract: Certain examples provide systems and methods for improved perinatal workflow. An example system includes a user interface to display a time continuum of live data for a selected patient. The user interface includes a compressed view of the time continuum of live data over a first time period; an expanded view of the time continuum of live data over a second time period, the second time period to be shorter than the first time period; one or more indicators to be associated with data shown in the expanded view, each indicator to indicate a point of interest in the data; a first control to change the second time period for the expanded view display; and a second control to mark an indicator with respect to the data shown in the expanded view of the time continuum of live data.